Centiva Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Centiva Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,500	Closed	-$413K	–	1640
2024 Q3	$413K	Buy	1,500 +500	+50%	+$130K	0.01%	1378
2024 Q2	$243K	Buy	+1,000	New	+$158K	﹤0.01%	1584
2023 Q4	–	Sell	-2,500	Closed	-$443K	–	1757
2023 Q3	$443K	Buy	+2,500	New	+$477K	0.01%	1006
2022 Q4	–	Sell	-5,000	Closed	-$1M	–	1344
2022 Q3	$1M	Hold	5,000	–	–	0.02%	623
2022 Q2	$729K	Buy	+5,000	New	+$709K	0.02%	762
2020 Q2	–	Sell	-1,300	Closed	-$141K	–	656
2020 Q1	$141K	Sell	1,300 -1,100	-46%	-$127K	0.01%	477
2019 Q4	$276K	Hold	2,400	–	–	0.01%	579
2019 Q3	$193K	Buy	+2,400	New	+$190K	0.01%	515

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Centiva Capital's ALNY Position: Q4 2024 in Review

Centiva Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 42 shares — an estimated $11.6K sold.

Centiva Capital first reported a position in ALNY in Q3 2019 and held it in 13 quarters. The position peaked at $793K in Q2 2021. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Centiva Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Centiva Capital sold 42 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $11.6K.
Centiva Capital first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 13 quarters.
Centiva Capital's Alnylam Pharmaceuticals position peaked at $793K in Q2 2021.
594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.